Prime Medicine Inc banner
P

Prime Medicine Inc
NASDAQ:PRME

Watchlist Manager
Prime Medicine Inc
NASDAQ:PRME
Watchlist
Price: 3.735 USD -2.73%
Market Cap: $674.4m

Prime Medicine Inc
Retained Earnings

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Prime Medicine Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
P
Prime Medicine Inc
NASDAQ:PRME
Retained Earnings
-$888.4m
CAGR 3-Years
-45%
CAGR 5-Years
-172%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Retained Earnings
-$15.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Retained Earnings
$13.7B
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Retained Earnings
$13.6B
CAGR 3-Years
28%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Retained Earnings
$35.8B
CAGR 3-Years
15%
CAGR 5-Years
27%
CAGR 10-Years
45%
No Stocks Found

Prime Medicine Inc
Glance View

Prime Medicine Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-10-20. Prime Medicine, Inc. is a United States-based biotechnology company. The firm is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The firm's Prime Editing, a transformative technology that addressed the cause of genetic disease. The firm's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.

PRME Intrinsic Value
0.214 USD
Overvaluation 94%
Intrinsic Value
Price $3.735
P

See Also

What is Prime Medicine Inc's Retained Earnings?
Retained Earnings
-888.4m USD

Based on the financial report for Dec 31, 2025, Prime Medicine Inc's Retained Earnings amounts to -888.4m USD.

What is Prime Medicine Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-172%

Over the last year, the Retained Earnings growth was -29%. The average annual Retained Earnings growth rates for Prime Medicine Inc have been -45% over the past three years , -172% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett